ZBH - Zimmer Biomet Holdings, Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
137.21
-0.74 (-0.54%)
As of 10:13AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close137.95
Open138.61
Bid137.63 x 1000
Ask137.77 x 800
Day's Range137.21 - 138.65
52 Week Range96.99 - 140.53
Volume89,481
Avg. Volume1,215,968
Market Cap28.1B
Beta (3Y Monthly)1.26
PE Ratio (TTM)N/A
EPS (TTM)-1.76
Earnings DateOct 24, 2019 - Oct 28, 2019
Forward Dividend & Yield0.96 (0.70%)
Ex-Dividend Date2019-06-27
1y Target Est148.08
Trade prices are not sourced from all markets
  • Why Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Could Be Worth Watching
    Simply Wall St.

    Why Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Could Be Worth Watching

    Let's talk about the popular Zimmer Biomet Holdings, Inc. (NYSE:ZBH). The company's shares received a lot of attention...

  • PR Newswire

    Zimmer Biomet's Innovative Treatment for Young Patients with Scoliosis Receives FDA Approval

    WARSAW, Ind., Aug. 16, 2019 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced U.S. Food and Drug Administration approval for The Tether™ for treatment of scoliosis, providing a fusion-less alternative for young patients requiring surgery. The current surgical treatment for scoliosis is an invasive operation involving large incisions, extensive soft tissue disruption and restriction of spinal motion with metal rods inserted along both sides of the spine to secure and align the vertebrae. Surgeons have tirelessly searched for alternative non-fusion surgical approaches to address scoliosis without limiting the skeletal development of these patients who are active and still growing. Zimmer Biomet's anterior vertebral body tethering (AVBT) solution, The Tether, uses a strong, flexible cord, rather than metal rods, to pull on the outside of a scoliosis curve to initially straighten the spine, while the inside of the curve is left free to grow.

  • PR Newswire

    Zimmer Biomet Holdings to Present at Morgan Stanley 17th Annual Global Healthcare Conference

    WARSAW, Ind. , Aug. 15, 2019 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, will participate in the Morgan Stanley 17 th Annual Global ...

  • PR Newswire

    Zimmer Biomet Holdings to Present at Wells Fargo Securities 2019 Healthcare Conference

    WARSAW, Ind. , Aug. 13, 2019 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, will participate in the Wells Fargo Securities 2019 Healthcare ...

  • GuruFocus.com

    Jeff Auxier Comments on Zimmer Biomet Holdings

    Guru stock highlight Continue reading...

  • GuruFocus.com

    Jeff Auxier's Auxier Asset Management Summer 2019 Market Commentary

    Discussion of markets and holdings Continue reading...

  • BioScrip Closes Option Care Merger, Incurs Wider Q2 Loss
    Zacks

    BioScrip Closes Option Care Merger, Incurs Wider Q2 Loss

    With the conclusion of BioScrip (BIOS)-Option Care consolidation, the newly formed company gets its new name Option Care Health, Inc. under the ticker symbol BIOS.

  • Orthofix Medical (OFIX) Beats on Q2 Earnings, Margins Down
    Zacks

    Orthofix Medical (OFIX) Beats on Q2 Earnings, Margins Down

    Orthofix Medical's (OFIX) Q2 performance across all business segments has been commendable, except for spinal implants.

  • Medical device sale boosts Partners bottom line
    American City Business Journals

    Medical device sale boosts Partners bottom line

    The sale of an orthopedic medical device boosted the bottom line of the state’s largest health care system, contributing to one of the highest operating margins the organization has experienced in years.

  • GuruFocus.com

    Gains in Knee Replacement Driving Zimmer Biomet Growth

    Shares near 52-week high after surpassing 2nd-quarter expectations Continue reading...

  • MoneyShow

    Zimmer Biomet- A Leader in Orthopedics

    Zimmer Biomet (ZBH) is a leader in orthopedic medicine. Products and solutions are used to treat patients suffering from disorders or injuries to bones, joints, or supporting soft tissues, explains Chuck Carlson, dividend reinvestment specialist and editor of DRIP Investor.

  • Thomson Reuters StreetEvents

    Edited Transcript of ZBH earnings conference call or presentation 26-Jul-19 12:30pm GMT

    Q2 2019 Zimmer Biomet Holdings Inc Earnings Call

  • Zimmer Biomet Holdings (ZBH) Q2 2019 Earnings Call Transcript
    Motley Fool

    Zimmer Biomet Holdings (ZBH) Q2 2019 Earnings Call Transcript

    ZBH earnings call for the period ending June 30, 2019.

  • PR Newswire

    Zimmer Biomet Recommends Shareholders Reject Mini-Tender Offer by TRC Capital Corporation

    WARSAW, Ind., July 26, 2019 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Corporation (TRC) to purchase up to one million shares of Zimmer Biomet common stock, or approximately 0.49 percent of the Company's outstanding shares as of the offer date of July 15, 2019, at a price of $115.35 per share in cash. TRC's offer price is approximately 4.4 percent lower than the $120.60 closing price of the Company's common stock on July 12, 2019, the last trading day before commencement of the offer, and approximately 14.2 percent lower than the $134.50 closing price of the Company's common stock on July 26, 2019. Zimmer Biomet does not endorse TRC's unsolicited mini-tender offer and recommends that shareholders not tender their shares in response to the offer.

  • Zimmer Biomet (ZBH) Beats on Q2 Earnings, Narrows '19 View
    Zacks

    Zimmer Biomet (ZBH) Beats on Q2 Earnings, Narrows '19 View

    Zimmer Biomet (ZBH) observes strength in the Asia Pacific and EMEA regions as well as in the S.E.T. business.

  • Benzinga

    Zimmer Biomet Reports Q2 Earnings Beat

    Zimmer Biomet Holdings Inc (NASDAQ: ZBH ) reported quarterly earnings of $1.93 per share, which beat the analyst consensus estimate of $1.91. This is a 0.52% increase over earnings of $1.92 per share from ...

  • Zimmer Biomet (ZBH) Q2 Earnings and Revenues Beat Estimates
    Zacks

    Zimmer Biomet (ZBH) Q2 Earnings and Revenues Beat Estimates

    Zimmer (ZBH) delivered earnings and revenue surprises of 0.52% and 0.34%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • TheStreet.com

    Zimmer Biomet Jumps on Second-Quarter Earnings Beat

    Shares of orthopedic device maker Zimmer Biomet jump after the company reports second-quarter earnings and sales that beat analysts' forecasts.

  • PR Newswire

    Zimmer Biomet Announces Second Quarter 2019 Financial Results

    - Net sales of $1.989 billion for the second quarter represent a decrease of 0.9% from the prior year period; an increase of 1.2% on a constant currency basis - Diluted earnings per share for the second ...

  • ZBH vs. MDT: Which Stock Should Value Investors Buy Now?
    Zacks

    ZBH vs. MDT: Which Stock Should Value Investors Buy Now?

    ZBH vs. MDT: Which Stock Is the Better Value Option?

  • Why Earnings Season Could Be Great for Zimmer Biomet (ZBH)
    Zacks

    Why Earnings Season Could Be Great for Zimmer Biomet (ZBH)

    Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • Can New Product Menu Aid Zimmer Biomet's (ZBH) Q2 Earnings?
    Zacks

    Can New Product Menu Aid Zimmer Biomet's (ZBH) Q2 Earnings?

    With consecutive product approvals, Zimmer Biomet (ZBH) becomes the first company on the global frontier with 510(k) clearance for Brain, Spine and Knee offerings on a single robotic platform.

  • Zimmer Biomet (ZBH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
    Zacks

    Zimmer Biomet (ZBH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

    Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Is Zimmer Biomet Holdings, Inc.'s (NYSE:ZBH) Balance Sheet A Threat To Its Future?
    Simply Wall St.

    Is Zimmer Biomet Holdings, Inc.'s (NYSE:ZBH) Balance Sheet A Threat To Its Future?

    Zimmer Biomet Holdings, Inc. (NYSE:ZBH), a large-cap worth US$25b, comes to mind for investors seeking a strong and...

  • Markit

    See what the IHS Markit Score report has to say about Zimmer Biomet Holdings Inc.

    Zimmer Biomet Holdings Inc NYSE:ZBHView full report here! Summary * Perception of the company's creditworthiness is positive * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ZBH with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ZBH. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $2.04 billion over the last one-month into ETFs that hold ZBH are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | PositiveThe current level displays a positive indicator. ZBH credit default swap spreads are near the lowest level of the last one year and indicate improvement in the market's perception of the company's credit worthiness.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.